Fig. 2.
Fig. 2. Clinical outcome in 11 renal transplantation patients with PTLD treated with decreasing immunosuppression and acyclovir. / The blue bar represents the time from kidney transplantation to the diagnosis of PTLD. The purple bar represents the time from initiation of therapy to last follow-up, death, or relapse (progression-free survival). Patient no. 2 died of sepsis 4 weeks after diagnosis of PTLD without a documented response. Patient no. 6 relapsed after a 25-month CR with IS taper and acyclovir. A second CR was achieved after withdrawal of IS and institution of rituximab therapy. A second relapse was then treated with high-dose antiviral therapy (zidovudine and ganciclovir), which led to a third CR (clinical, radiologic, and virologic).

Clinical outcome in 11 renal transplantation patients with PTLD treated with decreasing immunosuppression and acyclovir.

The blue bar represents the time from kidney transplantation to the diagnosis of PTLD. The purple bar represents the time from initiation of therapy to last follow-up, death, or relapse (progression-free survival). Patient no. 2 died of sepsis 4 weeks after diagnosis of PTLD without a documented response. Patient no. 6 relapsed after a 25-month CR with IS taper and acyclovir. A second CR was achieved after withdrawal of IS and institution of rituximab therapy. A second relapse was then treated with high-dose antiviral therapy (zidovudine and ganciclovir), which led to a third CR (clinical, radiologic, and virologic).

Close Modal

or Create an Account

Close Modal
Close Modal